Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANREO-PMO
2024-513809-31-00Phase 2Authorised
- Sponsor
- CHRU Nancy
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of potassium canrenoate in brain death, sponsored by CHRU Nancy. Primary endpoint: Hierarchical composite hemodynamic tolerance endpoint. Planned start Aug 2024; status: authorised.
02
Drugs
potassium canrenoate
03
Conditions
brain death
Beyond the preview
Go deeper on 2024-513809-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513809-31-00.